Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
| Status: | Recruiting |
|---|---|
| Conditions: | Parkinsons Disease, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | December 2010 |
| Contact: | Sara Varanese, M.D. |
| Email: | sara.varanese@nyumc.org |
| Phone: | 212-263-4838 |
The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time
sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in
the attention commonly reported by patients with more advanced Parkinson's disease (PD) and
Lewy body disease (LBD).
sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in
the attention commonly reported by patients with more advanced Parkinson's disease (PD) and
Lewy body disease (LBD).
The main aims of this study are:
1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia
thalamocortical network, measured through the Electroencephalography (EEG) frequency
analysis, are ameliorated by armodafinil.
Our main hypothesis is that armodafinil can restore the attention and improve cognitive
disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical
activity.
1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia
thalamocortical network, measured through the Electroencephalography (EEG) frequency
analysis, are ameliorated by armodafinil.
Our main hypothesis is that armodafinil can restore the attention and improve cognitive
disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical
activity.
Inclusion Criteria:
- Established criteria for diagnosis of PDD (Parkinsons Disease) {Emre M et al. Mov
Disord 2007;22:1689-707} and DLB (Lewy Bodies Disease) {McKeith et al. Neurology
2005;65:1863-72}
- Mini Mental State Examination (MMSE) score between <24; and/or Dementia Rating
- Scale-2 (DRS-2) score <134;
- Clinical Assessment of Fluctuation (CAF)>4;
- Stable anti-parkinsonian medication in the 4 weeks preceding the study
Exclusion Criteria:
- Use of cognitive enhancers (Donepezil, Rivastigmine, Galantamine, Modafinil,
Memantine) in the last 4 weeks:
Concomitant use of any medication contraindicated with modafinil/armodafinil; History of
alcohol and substances abuse. Use of medications known to alter the normal EEG activity in
humans during the study period (i.e. clonazepam) History of psychiatric disorders, other
than depression and psychiatric complication of PDD and DLB
We found this trial at
1
site
Click here to add this to my saved trials
